A detailed history of Assetmark, Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 10,489 shares of VKTX stock, worth $540,498. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,489
Previous 1,291 712.47%
Holding current value
$540,498
Previous $68,000 876.47%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$49.84 - $70.47 $458,428 - $648,183
9,198 Added 712.47%
10,489 $664,000
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $25,021 - $42,345
528 Added 69.2%
1,291 $68,000
Q1 2024

May 06, 2024

BUY
$17.4 - $94.5 $13,276 - $72,103
763 New
763 $62,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.